Lipopolysaccharide acts synergistically with the dengue virus to induce monocyte production of platelet activating factor and other inflammatory mediators

Achala Kamaladasa<sup>1</sup>, Laksiri Gomes<sup>1</sup>, Chandima Jeewandara<sup>1</sup>, N.L.A. Shyamali<sup>2</sup>, Graham S. Ogg \*<sup>3,4,5</sup> and Gathsaurie Neelika Malavige \*<sup>1,3</sup>

<sup>1</sup>Centre for Dengue Research, Department of Microbiology, <sup>2</sup>Department of Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Sri Lanka, <sup>3</sup>MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, OX3 9DS, UK, <sup>4</sup>Oxford NIHR Biomedical Research Centre and University of Oxford, OX3 9DS, UK, <sup>5</sup>Department of Dermatology, Churchill Hospital, Oxford, OX3 7LJ, UK.

Correspondence should be addressed to:

Prof. Neelika Malavige DPhil, FRCP, FRCPath

Centre for Dengue Research, Faculty of Medical Sciences,

University of Sri Jayawardanapura, Sri Lanka

Tel +94 (0) 772443193; Fax: +94 (0) 112802026

Email: gathsaurie.malavige@ndm.ox.ac.uk

\*Authors contributed equally

Running title: Platelet activating factor in dengue

#### **Abstract**

Background: Platelet Activating Factor (PAF) has been shown to be an important mediator of vascular leak in acute dengue. Antibody dependent enhancement (ADE) and microbial translocation has also shown to contribute to severe dengue. Since monocytes are one of the primary targets of the dengue virus (DENV) we sought to investigate if monocytes were a source of PAF, and the effect of ADE and microbial endotoxin (LPS) on DENV infected monocytes.

Methods: PAF and cytokine levels were evaluated in serial blood samples, in patients with acute dengue infection. The effect of ADE and LPS in production of PAF and cytokines from DENV infected primary human monocytes derived macrophages (MDMθ) was assessed. Gene expression analysis was undertaken to investigate mechanisms by which LPS potentiates PAF and cytokine production by DENV infected MDMθ.

Results: Serum PAF levels significantly correlated with both TNF-α (p<0.0001) and IL-1β (p<0.0001) in patients with acute DENV infection. Although primary human MDMθ produced inflammatory cytokines following infection with the DENV, they did not produce PAF following *in vitro* DENV infection alone, or in the presence of dengue immune serum. Levels of PAF produced by DENV infected MDMθ co-cultured with LPS was significantly higher than uninfected MDMθs co-cultured with LPS. Although TLR-4 was upregulated in uninfected MDMθs co-cultured with LPS, this upregulation was not significant in DENV infected MDMθ. Only expression of *RIG-I* was significantly up regulated (p<0.05) when DENV infected MDMθ were co-cultured with LPS.

Conclusion: LPS acts synergistically with the DENV to induce production of PAF and other inflammatory cytokines, which suggests that microbial translocation that has shown to occur in acute dengue, could contribute to dengue disease severity.

## ACCEPTED MANUSCRIPT

# Highlights

- Platelet activating factor (PAF) associates with inflammatory cytokines in acute dengue
- Monocyte derived macrophages produced inflammatory cytokines following infection with the DENV
- Monocyte derived macrophages did not produce PAF following DENV infection alone
- Antibody dependent enhancement did not induce production of PAF from monocytes
- Lipopolysaccharide acts synergistically with the DENV to induce production of PAF

Keywords: acute dengue; platelet activating factor; lipopolysaccharide; monocytes, inflammatory cytokines

#### 1.1 Introduction

Dengue viral infections are one of the most important mosquito borne viral infections in the world, and estimated to infect 390 million individuals annually (1). Since the year 1990, the global incidence of dengue has doubled every decade and apart from the morbidity due to acute illness, disability due to post dengue related chronic fatigue was estimated to be 186,000 to 1,415,000 years lived with disability in 2013 (2). Although dengue causes a significant mortality and morbidity, severe forms of dengue such as dengue hemorrhagic fever (DHF) occur only in a proportion of those with clinically apparent infections (3).

Endothelial dysfunction leading to increased vascular permeability is the hallmark of severe dengue infection (4). Although the exact timing of fluid leakage is not known, it becomes clinically detectable around 3-7 days of onset of illness. The critical phase of dengue infection is thought to last for 24 to 48 hours, following which the leaked fluid is reabsorbed and the patient usually recovers (3). Due to the temporary nature of the fluid leakage in dengue, it is thought that increased vascular permeability is likely to be due to changes in the endothelial electrical resistance and gap junction protein expression, rather than damage to the endothelium (4, 5). Many cytokines, protease mediators and more recently dengue NS1 have been shown to associate with vascular leak in acute dengue (6-9).

We recently reported that platelet activating factor (PAF) is an important mediator of vascular leak and also implicated altered sphingosine 1-phosphate levels as a further contributory mechanism (8, 10). We found that decrease in expression of the gap junction protein ZO-1 and reduction of the trans-endothelial electrical resistance by sera of patients

#### ACCIEPTIED MAINUSCRUPT

with acute dengue infection, was significantly inhibited when human umbilical endothelial cells were pre-treated with a PAF receptor blocker (10). PAF is a phospholipid mediator with many biological functions including induction of increased vascular permeability (11). It has been shown that human monocytes produce PAF in a bi-phasic pattern when stimulated with lipopolysaccharide (LPS), which was shown to be due to the effects cytokines such as TNFα and IL-1β (12, 13). PAF has been shown to activate transcription of NF-kB, resulting in expression of many inflammatory cytokines such as TNFα and IL-1β (12-14). We too have observed that PAF is produced in a bi-phasic pattern in patients with acute dengue (10). Since LPS was the main stimulus that resulted in bi-phasic production of PAF and other cytokines, it is possible that LPS plays a similar role in acute dengue infection. It has been shown that patients who develop plasma leakage during dengue infection have significantly higher levels of LPS than those who did not have plasma leakage (15, 16). It was also shown that higher levels of LPS in dengue patients correlated with the levels of inflammatory cytokines (15).

Monocytes and macrophages are one of the cells that are predominantly infected by the dengue virus in acute dengue infection (17-19). Dengue virus (DENV) infected monocytes have also been shown to contribute to endothelial dysfunction in the presence of enhancing antibodies (20). Monocytes and macrophages are also known to be an important source of PAF (12, 21). Since monocytes and macrophages are a primary target of the DENV and since they are also known to produce PAF, we set out to investigate if monocytes derived macrophages produced PAF when infected with the DENV and under antibody dependent enhancement (ADE). Since LPS has been shown to act on monocyte derived macrophages (MDMθ) and stimulate PAF in a bi-phasic manner, we also investigated if the LPS levels reported in patients with DHF, stimulated production of PAF from DENV infected MDMθ.

#### ACCEPTIED MANUSCRIPT

conditions of ADE, but LPS appeared to act synergistically with the DENV to induce MDMθ to produce PAF and other inflammatory cytokines.

#### 1.2 Methods

#### 1.2.1 Patients

In one of our previous studies, we had determined changes in PAF levels and disease severity in 36 adult patients with acute dengue infection (10). The changes in the levels of PAF over time in this cohort of patients with DF and DHF are described in this paper. In order to determine the relationship between PAF and other inflammatory cytokines, we used stored sera of these patients for the current study. In this cohort of 36 patients (described in detail in our previous paper), serial blood samples were taken in the morning (approximately around 6 a.m.) and again at 1.00p.m throughout the duration of the hospital stay. The onset of illness was defined as the time of onset of fever. All clinical features and laboratory induces were recorded several times each day from the time of admission to discharge from hospital. Clinical disease severity was classified according to the 2011 WHO dengue diagnostic criteria (3). Accordingly, patients with a rise in haematocrit above  $\geq$  20% of the baseline haematocrit or clinical or ultrasound scan evidence of plasma leakage in a patient was classified as having DHF. Shock was defined as having cold clammy skin, along with a narrowing of pulse pressure of  $\leq$  20 mmHg. Based on this definition 25 patients were diagnosed to have DHF and 11 DF.

#### 1.2.2 Ethics statement

The ethical approval was granted from the Ethical Review Committee of the University of Sri Jayawardanapura. All healthy individuals (n=5) who also participated in the study gave informed written consent.

## 1.2.3 Confirmation of acute dengue

Acute dengue infection was confirmed in the serum samples using the NS1 early dengue ELISA (Panbio, Australia). All assays were done in duplicate. Dengue was also confirmed in these patients with a commercial capture-IgM and IgG enzyme-linked immunosorbent assay (ELISA) (Panbio, Brisbane, Australia). The ELISA was performed and the results were interpreted according to the manufacturers' instructions. This ELISA assay has been validated as both sensitive and specific for primary and secondary dengue virus infections (22, 23).

# 1.2.4 Isolation and purification of monocytes

Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors (n=5) using Lymphoprep (Axis-Shield) density gradient centrifugation. The monocytes were positively selected from whole PBMCs using CD14 magnetic beads (Milteny Biotech) using MACS separation columns (Milteny Biotech, USA). The monocyte purity determined by flowcytometry and was between 90-95%.

After separation, monocytes were placed into a 96 well U bottom plate (20,000 monocytes/well) in RPMI (Life technologies, USA) supplemented with 10% AB negative human serum (Sigma), 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin (Sigma). All monocytes were incubated with IL-4 (25X10<sup>6</sup> mg/ml) at 37°C with 5% CO<sub>2</sub> for 48 hours before infecting with the DENV-3 as previously described (19). IL-4 was used as it has been shown to increase the infection rate of MDMθ and dendritic cells (19, 24).

#### 1.2.5. Virus propagation and titration

## ACCEPTED MANUSCRIPT

The DENV-3 CH53489 isolate was used in all experiments (kindly donated by Prof. Aravinda de Silva). The virus was propagated using the C6/36 cell lines and stored in aliquots at -80°C until used. The concentration of the virus was determined by plaque assays on BHK-21 cells and expressed as PFU/ml. Briefly, a BHK-21 monolayer was infected with a 10-fold serial dilution of virus, and incubated at 37 °C with 5% CO<sub>2</sub> for 4 days. After 4 days, the monolayer was fixed and stained with crystal violet and the number of plaques counted. All assays were done in triplicate.

## 1.2.6. Infection of monocytes with dengue virus

Infection with MDM0 was carried out as previously described (19). MDM0 isolated from healthy individuals were washed once with RPMI before infecting with the DENV-3 virus inoculum at an MOI of 1. Uninfected MDM0 were treated similarly to the infected MDM0 and incubated with Leibovitz medium (Sigma) as the negative control for the same duration of time as the infected MDM0s. After 90 minutes of virus absorption, the cells were washed again with RPMI and incubated in RPMI supplemented with 10% AB negative human serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin in a 5% CO2 at incubator 37 °C. The cells were stained with the primary antibody, anti DENV E glycoprotein antibody (Abcam, UK) and the secondary antibody Goat anti-Mouse IgG secondary antibody Alexa Fluor 488 (Abcam, UK). Cells were observed with Olympus X100 microscope (Olympus) after mounting on DAPI stain (Sigma-Aldrich) to confirm infection (Supplementary Fig 1).

The virus infected and uninfected MDM $\theta$  were incubated for a period of 24 to 96 hours in the presence and absence of LPS and dengue immune sera (please see below) to determine the effects of these on production of LPS and other inflammatory mediators. The viability of the infected and uninfected cells was  $\geq$  90% up to 96 hours following infection.

## 1.2.7. Determining the effect of lipopolysaccharide (LPS) on PAF production

As LPS was found to associate with disease severity in patients with acute dengue (15, 16) we proceeded to determine its effect on PAF production and production of other inflammatory cytokines in DENV infected monocytes. As the levels of LPS reported in patients with dengue in previous studies were in the range of 1 to 1000pg/ml (15), we used a mean value of 500pg/ml of LPS in our assays. Infected and uninfected MDMθ (20,000/well) from five healthy individuals were incubated for 96 hours in the presence an absence of LPS (500 pg/ml per well) and the culture supernatant was collected at 24, 48, 72 and 96 hour post infection (HPI) and stored in aliquots at -80°C. All experiments were done in duplicate.

To determine the effect of LPS on gene expression infected and uninfected MDM0 (100,000/well) from five healthy individuals were incubated for 24 hours in the presence and absence of LPS (500 pg/ml per well). RNA from the MDM0 was extracted and converted to cDNA using TaqMan Cells-to-CT kit (Applied Biosystems, USA) according to the manufacturer's instructions. The cDNA was stored in -20°C until gene expression analysis was done.

## 1.2.8. Determining if the presence of dengue antibodies stimulated production of PAF

The ADE experiments were done as previously described (25). Briefly, in order to determine the effects of DENV specific antibodies, serum from healthy volunteers with known serotype of past dengue infection was collected and pooled together (25-27). Pooled serum was heat inactivated before used in ADE experiments. The sera were incubated in dilutions of 1:5, 1:10 and 1:100 in RPMI media (Life technologies, USA) containing DENV3 at 37° C for 1

#### ACCIEPTIED MANUSCRIPT

hour prior to incubation with the purified monocytes. The primary human MDM0 were incubated with virus alone, or with virus/antibody complexes for 2 hours at 37° C at 5% CO<sub>2</sub>. Cells were centrifuged and the supernatants harvested at 24, 48, 72 and 96 hours to determine PAF and other inflammatory cytokine levels the supernatant. These experiments were done using 5 donors and each experiment was done in duplicate.

#### 1.2.9. Detection of cytokines and PAF

To measure levels of PAF (Cusabio, China), IL-10 (Mabtech, Sweden), TNF-α and IL-1β (Biolegend, USA) in serum samples of patients with acute dengue, quantitative ELISA was done in duplicate on all serum samples according to manufacturer's recommendations. In the MDMθ culture supernatants the levels of TNF-α, IL-10, IL-12p40 and IL-6 were determined using Luminex (Millipore, France) according to manufacturer's recommendations while PAF levels was determined using the same ELISA kit.

#### 1.2.10 Dengue virus quantification by RT-PCR

Viral RNA in MDMθ culture supernatants was extracted using QIAamp Viral RNA Mini Kit (Qiagen, USA) and transcribe to cDNA using High Capacity cDNA reverse transcription kit (Applied Biosystems, USA) as per the manufacturer's protocol. Quantitative real-time PCR was performed as previously described using the CDC real time PCR assay for detection of the DEV (28). Oligonucleotide primers and a dual labeled probe (FAM<sup>TM</sup> and TAMRA<sup>TM</sup>) for DEN 3 serotype was used (Life technologies, USA) based on published sequences (28). This assay was modified to quantify the DENV apart from quantitative analysis.

Real-time PCR was performed using 4×TaqMan® Fast Virus 1-Step Master Mix (Applied Biosystems, USA). The reaction was performed in an Applied Biosystems® 7500, 96-well

## ACCEPTED MANUSCRIPT

plate detection system. Following initial denaturation for 20 sec at 95°C, the reaction was carried out for 40 cycles of 3 sec at 95°C and 30 sec at 60°C. The threshold cycle value (Ct) for each reaction was determined by manually setting the threshold limit. Viral quantification (PFU/ml) of unknown samples was performed using the standard curve. All assays were done in triplicate.

#### 1.2.11. Quantification of gene expression using real time PCR

The real time PCR reaction was carried out using TaqMan® Gene Expression Master Mix Applied Biosystems) and TaqMan Gene Expression Assays (Applied Biosystems) to detect expression of following genes: TLR-4, NLR-3, MAPK-1, MAPK-3, MAPK-14, NF-\(\kappa\)B and DDX-58 (RIG-1). The reaction was performed in an Applied Biosystems® 7500, 96-well plate detection system. The reaction set was done as according to comparative C<sub>T</sub> method, with GAPDH as the endogenous control and the uninfected monocytes as the reference sample. Relative quantification values were taken from the analysis software (Applied Biosystems, USA). All assays were done in triplicate.

#### 1.2.12 Statistical analyses

Data analysis was performed using Graph Pad Prism 6.0 software. As the data were not normally distributed, differences in means were compared using the Mann-Whitney t test (two tailed). To determine positive and negative associations, the Spearman's correlation test was used (two tailed).

### 1.3 Results

# 1.3.1 Association of PAF levels with other inflammatory cytokines in patients with acute dengue

We found that TNF $\alpha$  levels were significantly higher in patients with DHF, when compared to those with DF, especially during the critical phase (from 120 to 168 hours) (Fig 1A) and also that IL-1 $\beta$  levels were also higher in patients with DHF (Fig 1B). Serum PAF levels significantly correlated with both serum TNF $\alpha$  levels (Spearman's R=0.56, p<0.0001) (Fig 1C) and serum IL-1 $\beta$  levels (Spearman's R=0.35, P<0.0001) (Fig 1D). However, serum PAF levels did not show any association with serum IL-10 levels.

## 1.3.2. Factors associated with production of PAF from monocytes

Although primary human monocytes were very permissive to DENV infection, we did not observe any PAF production by uninfected primary human MDM0s or by MDM0s infected with DENV-3 up to 96 hours post infection (Fig 2A).

Lipopolysaccharide (LPS) is a marker used for identification of microbial translocation (29) and significantly higher LPS levels have been detected in patients with acute dengue infection, especially in those with plasma leakage (15, 16). Furthermore, it has been shown

that human monocytes produce PAF in a bi-phasic pattern when stimulated with LPS, due to the actions of cytokines such as TNF $\alpha$  and IL-1 $\beta$  (12, 13). Since we did observe a bi-phasic pattern of PAF production in our patients (10), and since serum PAF levels significantly correlated with TNF $\alpha$  and IL1- $\beta$ , we determined if LPS stimulated PAF production from DEN-V infected MDM $\theta$ .

We found that as expected, LPS did stimulate PAF production from uninfected primary human MDMθ. However, the PAF production was significantly increased when LPS was co-cultured with DENV infected MDMθ (Fig 2A). The PAF levels were significantly higher at 24 and 48 hours after infection (P = 0.005 and P = 0.04 respectively), in DENV infected MDMθ in the presence of LPS when compared to the uninfected MDMθs. As the DENV and LPS appear to act synergistically to increase PAF production, we next proceeded to determine if the increased production was due to increase in virus infection. Using quantitative real time PCR, we determined the viral load in culture supernatants of primary human MDMθ of DENV infected MDMθs infected in the presence or absence of LPS up to 96 hours post infection. We found that there was no difference in the viral loads in the presence or absence of LPS up to 48 hours (Fig 2B). After 48 hours the DENV infected MDMθs, which were co-cultured with LPS showed a sharp decline.

Since LPS appears to enhance PAF production by DENV infected MDMθs, we also determined if LPS enhanced production of other inflammatory cytokines. We found that the levels of IL-6 and TNF-α were significantly increased in DENV infected MDMθs co-cultures with LPS when compared to uninfected MDMθs with LPS (Fig 2C and D). However, there was no significant difference observed with the IL-10 and IL-12 levels in DENV infected MDMθs in the presence of LPS and those which were co-cultured with LPS alone. Similar to

## ACCIEPTED MANUSCRIPT

the results seen with PAF, the DENV uninfected or infected MDM $\theta$ s in the absence of LPS did not produce any TNF $\alpha$  or IL-6. Although we did assay for IL-1 $\beta$ , the levels were below the level of detection in all samples. Therefore, LPS appears to act synergistically with the DENV to increase production of PAF, IL-6 and TNF $\alpha$ .

## 1.3.3. Effect of antibody dependent enhancement on PAF production by monocytes

ADE has been shown to increase production of many types of inflammatory cytokines such as IL-6, IL-8, IL-12p70 and TNFα, in DENV infected MDMθs. Since PAF production was not seen in MDMθs infected with the DENV alone, we sought to investigate if ADE had any role in stimulating production of PAF from MDMθs. We found that PAF was not produced from any of the primary human MDMθs, when incubated with varying concentrations of dengue immune sera. Although production of IL-10 and IL-12p40 cytokines was detected following DENV infection of MDMθs alone, a significant increase in these cytokine levels or in the production of IL-6 and TNFα were not detected in the levels of sera used in our experiments. (Fig 3).

## 1.3.4. Analysis of the effect of LPS on gene expression in DENV infected monocytes

Since we found that PAF, TNFα and IL-6 production was significantly up regulated in the presence of LPS in DENV infected MDMθs, we sought to investigate the signaling pathways that are responsible for changes in gene expression. Changes in the expression of the MAPK1, MAPK3, MAPK14, NLRP-3, TLR-4, NF-KB, RIG-1 were determined to identify different signaling pathways that are activated by LPS and the DENV: Of these seven genes, a significant difference was only observed in the expression of DDX58 (RIG-1). The expression of DDX58 (RIG-1) was significantly increased (p<0.05) in infected MDMθs

compared to LPS stimulated uninfected MDM0s (table 1). The expression of DDX58 (RIG-I) in infected MDM0s was further significantly increased (p<0.05) by LPS stimulation. Although TLR-4 expression was significantly increased in the MDM0s co-cultured with LPS as expected, the expression of TLR-4 was not significantly increased in the DENV-infected MDM0s co-cultured with LPS.

#### 1.4 Discussion

We previously found that PAF was significantly elevated in patients with DHF when compared to those with DF and using human endothelial umbilical cells (HUVECs), it was shown that PAF enhanced vascular leak in vitro (10). For instance, PAF in serum of patients with acute dengue was associated with reduced expression of tight junction proteins (ZO-1) and reduction in trans-endothelial resistance (TEER) of human endothelial cells (10). Therefore, we proceeded to investigate if serum PAF was associated with other inflammatory cytokines such as TNFα, IL-1β and IL-10 in this previously described cohort of patients with acute dengue. In this study we found that serum PAF correlated with two important inflammatory cytokines, in patients with acute dengue infection. The patterns of variation of TNF-α and IL-1β in patient sera mirrored the same bi-phasic pattern as seen with PAF. Therefore, it is possible that the same stimulus could be driving the production of PAF, TNF-α and IL-1β in patients.

Many cells such as monocytes, mast cells, other leucocytes, endothelial cells and platelets have been shown to produce PAF (30). Monocytes and macrophages are one of the main cell types infected with the DENV *in vivo* and are known to produce many types of inflammatory cytokines in acute dengue infection (4, 31). Therefore, we proceeded to investigate if DENV

infected MDM $\theta$  were a source of PAF and the factors responsible for production of PAF by MDM $\theta$ . Although monocytes are highly susceptible to infection with the DENV and in turn produce many inflammatory cytokines, DENV infection alone did not induce production of PAF from MDM $\theta$ s.

Many products released from DENV infected monocytes have been shown to induce endothelial dysfunction and to reduce expression of gap junction proteins (20, 32, 33). It was shown that endothelial activation, as assessed by expression of adhesion molecules, did not occur by culture supernatants of DENV MDM0s alone. The increased expression of ICAM-1, VCAM-1 and E-selectin only occurred in the presence of ADE (20). Antibody dependent enhancement (ADE) is thought to be an important mechanism that leads to severe disease in acute dengue, by enhancing infection by the DENV as opposed to neutralization (34, 35). U937 macrophages infected under ADE conditions have been shown to produce inflammatory mediators that disrupt cell apical junction complexes (36). Since we found that PAF was an important mediator of vascular leak in our previous studies, we proceeded to determine if dengue immune sera, simulated production of PAF by DENV infected MDM0 through ADE mechanisms. Although we did not observe any PAF production by DENV infected MDM0s under ADE conditions, DENV infection alone and ADE did induce the production of some inflammatory cytokines. As TNF-α has also been implicated with endothelium activation (20), other inflammatory mediators produced from monocytes apart from PAF could also lead to endothelium dysfunction.

Secondary bacteremia is known to occur in many patients with acute dengue, especially in those with more severe forms of clinical disease (37, 38). In addition, considerably high LPS levels have been detected in patients with acute dengue infection, especially in those with

plasma leakage (15, 16). Therefore, it is possible that microbial translocation is associated with severe clinical disease. Since LPS alone stimulates monocytes to produce PAF, we determined the effect of LPS on DENV infected MDMθs. We found that LPS acted synergistically with the DENV to induce production of PAF, TNF-α and IL-6 and it has no effect on IL-12 and IL-10 production. Although a previous report had shown that LPS inhibits DENV infection of monocytes, the LPS levels used in their *in vitro* experiments were 5 to 10 μg/ml (39), whereas we used 500pg/ml, which were the mean serum levels reported in patients with DHF (15, 16). Therefore, LPS could be playing a significant role in inducing production of inflammatory mediators from DENV infected MDMθs and thereby contributing to vascular leak in the critical early stages phase of infection. As the viral loads did not increase in DENV infected MDMθs co-cultured with LPS, the increase in production of these inflammatory mediators was unlikely to be purely due to increased viral replication.

As LPS appeared to act synergistically with the DENV in stimulating production of PAF, TNF- $\alpha$  and IL-6, we further proceeded to determine the mechanisms by which this is likely to occur. Although we evaluated the gene expression levels of TLR-4, MAP kinase pathways, NFkB1 pathways, the only relative increase in expression was seen in the RIG-I pathway in DENV infected MDM $\theta$  in the presence of LPS. As expected, expression of TLR-4 did increase significantly in MDM $\theta$ s co-cultured with LPS, but this increase was not significantly enhanced in DENV infected MDM $\theta$ s. RIG-I is a viral sensing pattern recognition receptor, which stimulates production of IFN- $\alpha$  and IFN- $\beta$  in infected cells (40). It has been shown that DENV nonstructural proteins interfere with downstream signaling pathways of RIG-I and thereby inhibit production of IFN $\alpha$ / $\beta$  (41). We found that RIG-I was significantly upregulated in DENV infected monocytes and it was further up-regulated in the presence of LPS. Upon activation of RIG-I, the signaling cascade that follows, leads to activation of IRF3

and NF-κB (40). However, we found that NF-κB expression was less in DENV infected monocytes when compared to monocytes co-cultured with LPS and the levels of NFκB1 expression were up-regulated in DENV infected cells co-cultured with LPS. Therefore, although RIG-I expression was up-regulated by the DENV, the up-regulation of downstream signaling pathways was less in DENV infected monocytes, which is consistent with the DENV inhibiting downstream signaling of RIG-I.

Although we found that PAF, IL-6 and TNF-α levels were significantly increased in DENV infected monocytes co-cultured with LPS, implying that the virus and LPS acted synergistically in increase production of these inflammatory mediators, this was not reflected in gene expression analysis. As only RIG-I was upregulated in DENV infected monocytes co-cultured with LPS, upregulation of RIG-I alone is unlikely to be associated with an increase in production of PAF and the other cytokines. Although the mechanisms of interaction of LPS and DENV to induce PAF and proinflammatory cytokine production is not explained by our study, higher levels of serum LPS in patients with acute dengue has shown to correlate with the degree of plasma leakage. Therefore, the mechanisms by which this occurs should be further investigated. Furthermore, since we only determined relative gene expression of RIG-I and other genes, it is possible that the RIG-I protein is not similarly up-regulated as our experiments were not designed to determine protein expression levels.

#### 1.5 Conclusion

In summary, PAF is produced by DENV infected monocytes in the presence of LPS and ADE does not appear to stimulate production of PAF from DENV infected monocytes. In addition, LPS appears to act synergistically with the DENV to induce production of PAF, TNF-α and IL-6. Since microbial translocation has shown to occur in acute dengue infection

## ACCEPTED MANUSCRIPT

and as higher LPS levels have been observed in patients with more severe clinical disease, LPS is likely to be important in the pathogenesis of dengue and associated vascular leak.

## 1.6 Acknowledgement

Funding was provided by the Centre for Dengue Research, University of Sri Jayewardenapura and the National Science Foundation (NSF/SCH/2013/03), Sri Lanka, and by the Medical Research Council (UK).

#### 1.7 Conflicts of interest

None

## 1.8 Glossary

PAF: Platelet activating factor

LPS: Lipopolysaccaride

**DENV: Dengue virus** 

DHF: Dengue Haemorrhagic Fever

DF: Dengue fever

MDMθ: monocyte derived macrophages

ADE: Antibody dependant enhancement

#### 1.8. Reference:

- 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7.
- 2. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet infectious diseases. 2016.
- 3. WHO, editor. Comprehensive guidelines for prevention and control of dengue fever and dengue haemorrhagic fever. SEARO, New Delhi, India: World Health Organization; 2011.
- 4. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clinical microbiology reviews. 2009;22(4):564-81.
- 5. Srikiatkhachorn A, Kelley JF. Endothelial cells in dengue hemorrhagic fever. Antiviral research. 2014;109C:160-70.
- 6. Appanna R, Wang SM, Ponnampalavanar SA, Lum LC, Sekaran SD. Cytokine factors present in dengue patient sera induces alterations of junctional proteins in human endothelial cells. The American journal of tropical medicine and hygiene. 2012;87(5):936-42.

## ACCEPTIED MANUSCRIPT

- 7. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP, Kalayanarooj S, Libraty DH, Green S, et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever. Journal of virology. 2007;81(4):1592-600.
- 8. Gomes L, Fernando S, Fernando RH, Wickramasinghe N, Shyamali NL, Ogg GS, et al. Sphingosine 1-phosphate in acute dengue infection. PloS one. 2014;9(11):e113394.
- 9. Beatty PR, Puerta-Guardo H, Killingbeck SS, Glasner DR, Hopkins K, Harris E. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Science translational medicine. 2015;7(304):304ra141.
- 10. Jeewandara C, Gomes L, Wickramasinghe N, Gutowska-Owsiak D, Waithe D, Paranavitane SA, et al. Platelet activating factor contributes to vascular leak in acute dengue infection. PLoS neglected tropical diseases. 2015;9(2):e0003459.
- 11. Walterscheid JP, Ullrich SE, Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. The Journal of experimental medicine. 2002;195(2):171-9.
- 12. Valone FH, Epstein LB. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol. 1988;141(11):3945-50.
- 13. Han SJ, Ko HM, Choi JH, Seo KH, Lee HS, Choi EK, et al. Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-kappa B (NF-kappa B). The Journal of biological chemistry. 2002;277(47):44715-21.
- 14. Im SY, Han SJ, Ko HM, Choi JH, Chun SB, Lee DG, et al. Involvement of nuclear factor-kappa B in platelet-activating factor-mediated tumor necrosis factor-alpha expression. European journal of immunology. 1997;27(11):2800-4.

## ACCEPTIED MANUSCRIPT

- 15. van de Weg CA, Pannuti CS, de Araujo ES, van den Ham HJ, Andeweg AC, Boas LS, et al. Microbial translocation is associated with extensive immune activation in dengue virus infected patients with severe disease. PLoS neglected tropical diseases. 2013;7(5):e2236.
- 16. van de Weg CA, Koraka P, van Gorp EC, Mairuhu AT, Supriatna M, Soemantri A, et al. Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. J Clin Virol. 2012;53(1):38-42.
- 17. Torrentes-Carvalho A, Azeredo EL, Reis SR, Miranda AS, Gandini M, Barbosa LS, et al. Dengue-2 infection and the induction of apoptosis in human primary monocytes.

  Memorias do Instituto Oswaldo Cruz. 2009;104(8):1091-9.
- 18. Wong KL, Chen W, Balakrishnan T, Toh YX, Fink K, Wong SC. Susceptibility and response of human blood monocyte subsets to primary dengue virus infection. PloS one. 2012;7(5):e36435.
- 19. Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS pathogens. 2008;4(2):e17.
- 20. Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. Journal of virology. 1997;71(6):4226-32.
- 21. Mariano F, Bussolati B, Migliori M, Russo S, Triolo G, Camussi G. Platelet-activating factor synthesis by neutrophils, monocytes, and endothelial cells is modulated by nitric oxide production. Shock. 2003;19(4):339-44.
- 22. Vaughn DW, Nisalak A, Solomon T, Kalayanarooj S, Nguyen MD, Kneen R, et al. Rapid serologic diagnosis of dengue virus infection using a commercial capture ELISA that

distinguishes primary and secondary infections. The American journal of tropical medicine and hygiene. 1999;60(4):693-8.

- 23. Sang CT, Cuzzubbo AJ, Devine PL. Evaluation of a commercial capture enzymelinked immunosorbent assay for detection of immunoglobulin M and G antibodies produced during dengue infection. Clinical and diagnostic laboratory immunology. 1998;5(1):7-10.
- 24. Schaeffer E, Flacher V, Papageorgiou V, Decossas M, Fauny JD, Kramer M, et al. Dermal CD14(+) Dendritic Cell and Macrophage Infection by Dengue Virus Is Stimulated by Interleukin-4. The Journal of investigative dermatology. 2015;135(7):1743-51.
- 25. Chaichana P, Okabayashi T, Puiprom O, Sasayama M, Sasaki T, Yamashita A, et al. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PloS one. 2014;9(3):e92173.
- 26. Boonnak K, Slike BM, Donofrio GC, Marovich MA. Human FcgammaRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol. 2013;190(11):5659-65.
- 27. Luo YY, Feng JJ, Zhou JM, Yu ZZ, Fang DY, Yan HJ, et al. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody. BMC microbiology. 2013;13:194.
- 28. Santiago GA, Vergne E, Quiles Y, Cosme J, Vazquez J, Medina JF, et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. PLoS neglected tropical diseases. 2013;7(7):e2311.
- 29. Marchetti G, Tincati C, Silvestri G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clinical microbiology reviews. 2013;26(1):2-18.
- 30. Hanahan DJ. Platelet activating factor: a biologically active phosphoglyceride. Annual review of biochemistry. 1986;55:483-509.

- 31. Sun P, Kochel TJ. The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. The Scientific World Journal. 2013;2013:843469.
- 32. Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, Tung YC, et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. The Journal of general virology. 2006;87(Pt 12):3623-30.
- 33. Ong SP, Lee LM, Leong YF, Ng ML, Chu JJ. Dengue virus infection mediates HMGB1 release from monocytes involving PCAF acetylase complex and induces vascular leakage in endothelial cells. PloS one. 2012;7(7):e41932.
- 34. Acosta EG, Bartenschlager R. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development. Expert review of vaccines. 2015:1-16.
- 35. Ng JK, Zhang SL, Tan HC, Yan B, Maria Martinez Gomez J, Tan WY, et al. First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies. PLoS pathogens. 2014;10(4):e1004031.
- 36. Puerta-Guardo H, Raya-Sandino A, Gonzalez-Mariscal L, Rosales VH, Ayala-Davila J, Chavez-Mungia B, et al. The cytokine response of U937-derived macrophages infected through antibody-dependent enhancement of dengue virus disrupts cell apical-junction complexes and increases vascular permeability. Journal of virology. 2013;87(13):7486-501.
- 37. Premaratna R, Dissanayake D, Silva FH, Dassanayake M, de Silva HJ. Secondary bacteraemia in adult patients with prolonged dengue fever. The Ceylon medical journal. 2015;60(1):10-2.

## ACCEPTED MANUSCRIPT

- 38. Lahiri M, Fisher D, Tambyah PA. Dengue mortality: reassessing the risks in transition countries. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(10):1011-6.
- 39. Chen YC, Wang SY, King CC. Bacterial lipopolysaccharide inhibits dengue virus infection of primary human monocytes/macrophages by blockade of virus entry via a CD14-dependent mechanism. Journal of virology. 1999;73(4):2650-7.
- 40. Kell AM, Gale M, Jr. RIG-I in RNA virus recognition. Virology. 2015;479-480:110-21.
- 41. Green AM, Beatty PR, Hadjilaou A, Harris E. Innate immunity to dengue virus infection and subversion of antiviral responses. Journal of molecular biology. 2014;426(6):1148-60.

Table 1

Name of gene	Expression in	Expression in	Expression in
	uninfected	infected monocytes	infected
	monocytes+LPS	- LPS	monocytes+LPS
	Mean (±SEM)	Mean (±SEM)	Mean (±SEM)
MAPK1	0.92 (0.16)	0.91 (0.22)	0.92 (0.2)
ACADKO	0.04 (0.05)	0.01 (0.17)	0.54 (0.00)
MAPK3	0.94 (0.25)	0.81 (0.17)	0.54 (0.08)

## ACCIEPTIED MANUSCRIPTI

MAPK14	1.92 (0.9)	1.14 (0.14)	0.99 (0.17)
NLRP-3	2.05 (1.02)	0.82 (0.24)	0.9 (0.27)
ΝΕΚβ1	3.88 (1.0)	0.99 (0.26)	3.1 (0.84)
DDX58	5.19 (1.9)	15.37 (4.4) *	18.02 (7.84) *
TLR-4	0.12 (0.11)	1.4 (0.67)	0.77 (0.31)

Table 1: Relative expression of different genes in relation to the house keeping gene (GAPDH) in DENV infected monocytes, DENV infected monocytes co-cultured with LPS and uninfected monocytes co-cultured with LPS. \* indicates when significant changes were observed. The values expressed are all positives and none of the genes were downregulated relative to GAPDH.

## Figures:

Fig 1: Levels of TNFα and IL-1β in patients with acute dengue and their association with serum PAF levels. The solid line represents the levels in patients with DHF and the dotted line patients with DF.

Fig 1A: Serum TNFα levels in patients with DF (n=11) and DHF (n=25), throughout the course of their illness. The dots indicate the mean and the SEM.

Fig 1B: Serum IL-1 $\beta$  levels in patients with DF (n=11) and DHF (n=25), throughout the course of their illness. The dots indicate the mean and the SEM.

### Fig 2: LPS enhances cytokine production by DEN-V infected monocytes.


Monocytes were isolated from healthy donors PBMC by CD14 magnetic beads using MACS separation columns, and infected with DEN-V at MOI of 1. PAF production was assessed in infected and uninfected monocytes in the presence and absence of LPS (500pg/ml)(A). Viral loads were also assessed in culture supernatants in DENV infected monocytes in the presence and absence of LPS and were expressed as plaque forming units (B). \* p<0.05 \*\*p<0.01The levels of IL-6 (C) and TNFα (D) were measured in the supernatant by ELISA. N=5 Bars show mean and SEM \*p<0.05 \*\*p<0.01 \*\*\*p<0.005


# Fig 3: Pattern of cytokine secretion by DENV-3 infected monocytes in the presence of varying concentrations of dengue immune sera

Monocytes isolated from healthy donors PBMC by CD14 magnetic beads using MACS separation columns, were infected with the DENV-3 virus at a MOI of 1 in the presence of varying concentrations of DENV immune sera up to 96 hours. The levels of (A) IL-6, (B) TNF-α, (C) IL-10 and IL-12p40 (D) were measured in the supernatant by ELISA. N=5.

# Supplementary figure 1 Detection of DENV infected monocytes with immunofluorescence

Monocytes were infected at MOI 1 with DENV-3.DENV infected cells were detected by using anti-dengue virus E glycoprotein primary antibody and Alexa Fluor 488 (green) conjugated secondary antibody, together with DAPI stain (blue)








Figure 1




Fig 2




Fig 3

#### ACCEPTIED MANUSCRUPT

